Navigation
Market Outlook Stock Screener Dividend Calendar Event Calendar Rating of shares Markets News
Try free
Biogen NASDAQ BIIB
$194.11 0.0000 0.0000%
Today share price
USA
Sector: Healthcare Industry: Biotechnology
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Index: 19 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

28.28B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
34.17B
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
0.47
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
145.70M
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-24.99 %
Upcoming events Biogen All events
24.04.2024 Financial Report 1st Quarter 2024
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart Biogen

Stock analysis Biogen

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

More
24.36 14.80
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

More
1.91 3.69
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

More
18.69 9.65
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

More
3.22 -0.17
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

More
7.85 11.19

Price change Biogen per year

223.25$ 427.50$
Min Max

Summary analysis Biogen

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure Biogen

Revenue and net income Biogen

All parameters
Stock news Biogen All news
13 February в 18:55

Biogen Promised a Return to Growth. Why the Stock Is Dropping.

13 February в 15:29

Biogen’s quarterly results miss expectations amid slow launch of Alzheimer’s treatment

13 February в 00:35

Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission

13 February в 00:35

Biogen's Skyclarys Treatment for Friedreich's Ataxia Authorized by European Commission

31 January в 17:00

Biogen Ends Development of Alzheimer’s Drug Aduhelm

31 January в 17:00

Biogen Ends Development of Alzheimer’s Drug Aduhelm

31 January в 16:25

Biogen Ends Aduhelm Program in Shift of Alzheimer’s Resources

31 January в 16:00

Biogen halts development of controversial Alzheimer’s drug

11 January в 16:30

Acorda Therapeutics: Biogen Ending Fampyra Collaboration

11 January в 16:30

Acorda Therapeutics: Biogen Ending Fampyra Collaboration

19 December 2023 в 15:55

Biogen ‘welcomes’ EC decision to revoke CMAs for generic versions of Tecfidera

19 December 2023 в 15:45

Biogen: European Commission Revokes Authorization For Generic Versions of Tecfidera Drug

19 December 2023 в 15:45

Biogen: European Commission Revokes Authorization For Generic Versions of Tecfidera Drug

8 November 2023 в 15:15

Biogen quarterly results top estimates despite complex launch of new Alzheimer’s treatment

8 November 2023 в 01:45

Biogen's Earnings Won't Be the Focus. Watch for Updates on Its Alzheimer's Drug.

8 November 2023 в 00:35

Biogen Earnings Are Soon. What to Watch.

26 October 2023 в 17:40

Biogen and Eisai’s Revised Alzheimer’s Drug Works, but Safety Questions Linger

26 October 2023 в 00:30

Biogen and Eisai release new Alzheimer’s drug data that may support wider uptake

4 October 2023 в 17:40

Что можно ожидать от акций Biogen

29 September 2023 в 23:30

Biogen gets FDA approval for biotech treatment similar to Roche’s Actemra

About company Biogen

Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, BAN2401, BIIB092, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB111 and BIIB112 to treat ophthalmology related diseases; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and TMS-007 to treat acute neurology; BIIB074 and BIIB095 for neuropathic pain; and SB11 and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Bristol-Myers Squibb Company; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Ginkgo Bioworks; Capsigen Inc.; and Mirimus, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
Address:
225 Binney Street, Cambridge, MA, United States, 02142
Company name: Biogen
Issuer ticker: BIIB
ISIN: US09062X1037
Country: USA
Exchange: NASDAQ
Currency: $
IPO date: 1991-09-16
Sector: Healthcare
Industry: Biotechnology
Site: https://www.biogen.com

On which stock exchange are Biogen (BIIB) stocks traded?

Biogen (BIIB) stocks are traded on NASDAQ.

What is the ticker of Biogen stocks (BIIB)?

The stock ticker of Biogen’s stocks or in other words, the code is BIIB. The stocks are currently listed on the NASDAQ exchange.

In which sector and industry does Biogen (BIIB) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, Biogen (BIIB) belongs to the «Healthcare» sector and the «Biotechnology» industry.

In what currency are Biogen (BIIB) stocks traded?

Biogen (BIIB) stocks are traded on the NASDAQ exchange in dollars.

What is the price of Biogen (BIIB) stocks today?

The current price of Biogen stocks on 23.04.2024 is 194.11 dollars. per share.

What is the dynamics of Biogen (BIIB) stocks from the beginning of the year?

Biogen (BIIB) quotes have increased by -27.49% from the beginning of the year up to 194.11 dollars. per 1 stocks.

How much did Biogen (BIIB) stocks increase in апреле 2024?

This month Biogen (BIIB) quotes have increased by -9.64% to 194.11 dollars. per share.

How much are Biogen (BIIB) stocks worth?

Today, on October, 23.04.2024 Biogen’s (BIIB) stocks cost 194.11 dollars..

What is the market capitalization of Biogen (BIIB)?

Capitalization is the market value of Biogen (BIIB) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 23.04.2024, the market capitalization of Biogen (BIIB) is estimated at about 28281827000 dollars.